FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1564-1568 May 27, 1993 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: We are pleased that Figueroa et al. (Dec. 3 issue)¹ have reaffirmed the effectiveness of alglucerase (Ceredase) in reducing the manifestations of Gaucher's disease with a previously published,^2,3 relatively low-dose regimen. However, we believe that the data presented are not adequate to conclude that a lower-dose regimen with frequent administration is equivalent to a higher-dose regimen given every two weeks. The comparison of the data obtained in this study with those in other studies,^4,5 though suggestive, is less than rigorous in providing convincing evidence of comparable responses to therapy. The variability in the progression and manifestations of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Mankin, H. J., Rosenthal, D. I., Xavier, R. (2001). Gaucher Disease : New Approaches to an Ancient Disease. JBJS 83: 748-763 [Full Text]  
• Beutler, E. (1993). Modern Diagnosis and Treatment of Gaucher's Disease. Arch Pediatr Adolesc Med 147: 1175-1183 [Abstract]